Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for Kisunla.

Lilly is also developing oral therapies for its gastroenterology pipeline.

The first ever drug treatment to target the underlying causes of Alzheimer’s disease has become the first alternative ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and ...

Among healthcare ETFs, VHT stands out in my view as the most representative of the sector, in terms of performance, risk, and ...

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

The Therapeutic Goods Administration has approved a new drug tipped to revolutionise the treatment of hundreds of thousands of Australians suffering through early-stage Alzheimer’s disease.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Sarrah Strimel Bentley and her boyfriend, James, were walking their dog at sunset when she felt an itch under her armpit. She ...